Literature DB >> 22619254

Estrogen provokes the depressant effect of chronic nicotine on vagally mediated reflex chronotropism in female rats.

Mahmoud M El-Mas1, Hanan M El-Gowelli, Sahar M El-Gowilly, Mohamed A Fouda, Mai M Helmy.   

Abstract

We recently reported that acute nicotine impairs reflex tachycardic activity in estrogen-depleted, but not estrogen-repleted, female rats, suggesting a restraining influence for estrogen against the nicotine effect. In this study, we tested whether the baroreflex-protective effect of estrogen can be replicated when nicotine was administered chronically. We also report on the dose dependence and autonomic modulation of the nicotine-baroreflex interaction. The effects of nicotine (0.5, 1, or 2 mg/kg/day for 14 days) on baroreflex curves relating changes in heart rate to increases [phenylephrine (PE)] or decreases [sodium nitroprusside (SNP)] in blood pressure were evaluated in sham-operated (SO), ovariectomized (OVX), and estrogen-replaced OVX (OVXE(2)) rats. Slopes of the curves were taken as a measure of baroreflex sensitivity (BRS(PE) and BRS(SNP)). In SO rats, both reflex bradycardic and tachycardic responses were attenuated by nicotine in a dose-related fashion. In nicotine-treated rats, blockade of β-adrenergic (propranolol), but not muscarinic (atropine), receptors caused additional reductions in reflex chronotropic responses, implying that nicotine selectively impairs reflex vagal activity. OVX selectively decreased BRS(PE) but not BRS(SNP) and abolished the nicotine-induced impairment of either response. These effects of OVX were reversed after treatment with estrogen or the estrogen receptor modulator raloxifene. In atropine-treated rats, comparable BRS values were demonstrated in all rat preparations regardless of the estrogen or nicotine milieu. Collectively, the inhibition of vagal activity accounts for the depressant effect of chronic nicotine on baroreflex activity. Furthermore, contrary to nicotine's acute effects, the baroreflex-attenuating effect of chronic nicotine is exacerbated by estrogen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22619254     DOI: 10.1124/jpet.112.191940

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Electronic cigarette exposure disrupts blood-brain barrier integrity and promotes neuroinflammation.

Authors:  Nathan A Heldt; Alecia Seliga; Malika Winfield; Sachin Gajghate; Nancy Reichenbach; Xiang Yu; Slava Rom; Amogha Tenneti; Dana May; Brian D Gregory; Yuri Persidsky
Journal:  Brain Behav Immun       Date:  2020-03-31       Impact factor: 7.217

2.  Gender differences in first and secondhand smoke exposure, spirometric lung function and cardiometabolic health in the old order Amish: A novel population without female smoking.

Authors:  Robert M Reed; Mark T Dransfield; Michael Eberlein; Michael Miller; Giora Netzer; Mary Pavlovich; Toni I Pollin; Steven M Scharf; Alan R Shuldiner; Don Sin; Braxton D Mitchell
Journal:  PLoS One       Date:  2017-03-31       Impact factor: 3.240

3.  The α7-nAChR/heme oxygenase-1/carbon monoxide pathway mediates the nicotine counteraction of renal inflammation and vasoconstrictor hyporeactivity in endotoxic male rats.

Authors:  Abdalla M Wedn; Sahar M El-Gowilly; Mahmoud M El-Mas
Journal:  Inflamm Res       Date:  2020-01-02       Impact factor: 6.986

4.  PI3K/Akt-independent NOS/HO activation accounts for the facilitatory effect of nicotine on acetylcholine renal vasodilations: modulation by ovarian hormones.

Authors:  Eman Y Gohar; Sahar M El-gowilly; Hanan M El-Gowelli; Maha A El-Demellawy; Mahmoud M El-Mas
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

5.  Impairment of nitric oxide synthase but not heme oxygenase accounts for baroreflex dysfunction caused by chronic nicotine in female rats.

Authors:  Mohamed A Fouda; Hanan M El-Gowelli; Sahar M El-Gowilly; Laila Rashed; Mahmoud M El-Mas
Journal:  PLoS One       Date:  2014-05-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.